Indo Us Bio-Tech FY26 net profit falls 19.3% to ₹1,312.29 lakh

Indo Us Bio-Tech Limited reported a 19.3% decline in net profit to ₹1,312.29 lakh for the financial year ended March 31, 2026, despite a 6.4% rise in revenue from operations to ₹11,049.33 lakh. The company’s Board of Directors approved the standalone audited financial results for the quarter and year ended March 31, 2026, at a meeting held on May 29, 2026.

For the quarter ended March 31, 2026, the company recorded a net profit of ₹197.17 lakh, a decrease from ₹368.48 lakh in the corresponding period of the previous year. Revenue from operations for the quarter stood at ₹2,604.62 lakh, compared to ₹3,350.41 lakh in the same period last year. Total income for the year was ₹11,049.33 lakh, up from ₹10,402.04 lakh in the prior year.

Financial Performance

The company’s earnings per share (EPS) for the year ended March 31, 2026, stood at ₹6.54, down from ₹8.11 in the previous year. Finance costs for the year increased to ₹224.33 lakh from ₹148.82 lakh in FY25. The statutory auditors, Gautam N Associates, expressed an unmodified opinion on the standalone financial results.

Metric	Year Ended March 31, 2026 (₹ in Lakhs)	Year Ended March 31, 2025 (₹ in Lakhs)
Revenue from Operations	11,049.33	10,402.04
Total Income	11,049.33	10,402.04
Total Expenses	9,657.31	8,748.98
Net Profit	1,312.29	1,626.74
EPS (Basic)	6.54	8.11

Balance Sheet and Cash Flows

The company’s total assets as of March 31, 2026, stood at ₹13,309.67 lakh, an increase from ₹9,784.27 lakh in the previous year. Inventories rose significantly to ₹9,905.37 lakh from ₹7,068.64 lakh. Cash and cash equivalents improved to ₹612.30 lakh from ₹24.78 lakh. The company reported that no dividend was declared or proposed for the year ended March 31, 2026.

Net cash from operating activities for the year was negative at ₹(1,258.06) lakh, compared to ₹141.93 lakh in the previous year. The company utilized ₹150.01 lakh in investing activities and generated ₹1,995.59 lakh from financing activities. The auditors noted that confirmations for certain trade receivables, payables, and loans were yet to be received.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.55%	-9.33%	-18.26%	-29.39%	-46.94%	-69.52%

Indo Us Bio Tech Limited has announced that its board of directors will meet on Friday, May 29, 2026. The primary agenda for the meeting includes the consideration of the audited financial results for the fourth quarter and the fiscal year ended March 31, 2026, in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agenda Items

The board will deliberate on several key financial documents. Specifically, the directors will consider:

The Audited Financial Results for the fourth quarter and year ended March 31, 2026.
The audited Balance Sheet as at March 31, 2026.
The Statement of Profit and Loss for the year ended March 31, 2026.
Other corporate matters as may be brought before the board.

Trading Window Closure

In compliance with regulatory norms, the company has informed the exchanges regarding the closure of the trading window. The window was closed on April 1, 2026, and will remain shut until May 30, 2026. This closure period includes both the start and end dates to ensure confidentiality and prevent insider trading during the sensitive period surrounding the financial results announcement.

The meeting notice was signed by Ms. Dimpy Joshi, Company Secretary & Compliance Officer, on behalf of indo us bio-tech .